Subscribe to RSS
DOI: 10.1055/a-1449-4054
Update 2021: COVID-19 aus Sicht der Gastroenterologie
Update 2021: COVID-19 from the perspective of gastroenterology
Wie bereits in der Frühphase der COVID-19-Pandemie berichtet, ist bei 15–20 % der Infizierten auch der Gastrointestinaltrakt betroffen. In einer kleinen Gruppe der Patienten treten ausschließlich gastrointestinale Symptome auf. In diesem Update werden aktuelle Daten zur Beteiligung des Gastrointestinaltrakts bei COVID-19 sowie neue Erkenntnisse über zugrunde liegende Mechanismen und über den Einfluss gastrointestinaler Symptome auf den Krankheitsverlauf besprochen.
Abstract
During COVID 19 pandemic patients typically present with respiratory symptoms. However, in a significant number of patients the gastrointestinal tract is also involved in the disease. Up to 20 % of patients suffering from gastrointestinal symptoms. New insights in pathophysiological aspects might open new therapeutic concepts. This up-date includes current data regarding epidemiology of gastrointestinal symptoms in COVID 19, its role for prognosis and specific risks in relation to immunosuppressive therapies and underlying diseases.
Publication History
Article published online:
13 July 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Bezzio C, Saibeni S, Variola A. et al Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020; 69 (07) 1213-1217 DOI: 10.1136/gutjnl-2020-321411. . Epub 2020 Apr 30
- 2 Brenner EJ, Ungaro RC, Gearry RB. et al Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology 2020 Aug 2020; 159 (02) 481-491.e3 DOI: 10.1053/j.gastro.2020.05.032. . Epub 2020 May 18
- 3 Mao R, Qiu Y, He JS. et al Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5 (07) 667-678 DOI: 10.1016/S2468-1253(20)30126-6. . Epub 2020 May 12
- 4 Ungaro RC, Brenner EJ, Gearry RB. et al Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021; 70 (04) 725-732 DOI: 10.1136/gutjnl-2020-322539. . Epub 2020 Oct 20
- 5 Bezzio C, Manes G, Bini F. et al Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds. Gut 2021; 70 (03) 623-624 DOI: 10.1136/gutjnl-2020-321760. . Epub 2020 Jun 17
- 6 Neurath MF. COVID-19 and immunomodulation in IBD. Gut 2020; 69 (07) 1335-1342 DOI: 10.1136/gutjnl-2020-321269. . Epub 2020 Apr 17
- 7 Xiao F, Tang M, Zheng X. et al Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158 (06) 1831-1833.e3 DOI: 10.1053/j.gastro.2020.02.055. . Epub 2020 Mar 3
- 8 Wölfel R, Corman VM, Guggemos W. et al Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581: 465-469 DOI: 10.1038/s41586-020-2196-x. . Epub 2020 Apr 1
- 9 Weber S, Hellmuth JC, Scherer C. et al. Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study. Gut 2021; DOI: 10.1136/gutjnl-2020-323800.
- 10 Goyal H, Sachdeva S, Perisetti A. et al Hyperlipasemia and Potential Pancreatic Injury Patterns in COVID-19: A Marker of Severity or Innocent Bystander?. Gastroenterology 2021; 160 (03) 946-948.e2 DOI: 10.1053/j.gastro.2020.10.037. . Epub 2020 Oct 28
- 11 Pandanaboyana S, Moir J, Leeds JS. et al. SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study. Gut 2021; DOI: 10.1136/gutjnl-2020-323364.